Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023
December 10, 2023 11:00 ET
|
Jasper Therapeutics
REDWOOD CITY, Calif., Dec. 10, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy...
Jasper Announces First Patient Dosed in Phase 1b/2a Clinical Study of Briquilimab in Chronic Spontaneous Urticaria
November 30, 2023 08:00 ET
|
Jasper Therapeutics
REDWOOD CITY, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
Jasper Therapeutics to Participate at Upcoming Medical and Investor Conferences
November 08, 2023 16:30 ET
|
Jasper Therapeutics
REDWOOD CITY, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy...
Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023
November 02, 2023 09:00 ET
|
Jasper Therapeutics
REDWOOD CITY, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy...
Jasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of Directors
November 01, 2023 08:00 ET
|
Jasper Therapeutics
REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy...
Jasper Therapeutics to Host Key Opinion Leader Webinar on the Potential of Briquilimab for Chronic Urticaria on October 11, 2023
October 09, 2023 08:30 ET
|
Jasper Therapeutics
REDWOOD CITY, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy...
Jasper Therapeutics Announces IND Clearance for Phase 1b/2a Study of Subcutaneous Briquilimab in Chronic Spontaneous Urticaria
October 09, 2023 08:00 ET
|
Jasper Therapeutics
First Patient Expected to be Dosed by Year-end 2023; Early Data Expected by Mid-2024 Clinical Study in Chronic Inducible Urticaria Planned to Commence in Early 2024 REDWOOD CITY, Calif., Oct. 09,...
Jasper Therapeutics Appoints Herb Cross as Chief Financial Officer
September 25, 2023 08:00 ET
|
Jasper Therapeutics
REDWOOD CITY, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody...
Jasper Therapeutics to Present New Positive Data on Briquilimab Conditioning in Patients with Fanconi Anemia at the 2023 Fanconi Anemia Research Fund Scientific Symposium
September 21, 2023 08:00 ET
|
Jasper Therapeutics
All three Fanconi Anemia patients treated with briquilimab achieved full donor engraftment and full blood count recoveryBriquilimab was well tolerated without any complicationsStudy expansion to Phase...
Jasper Therapeutics to Present at the Cantor Fitzgerald 2023 Global Healthcare Conference
September 15, 2023 08:00 ET
|
Jasper Therapeutics
REDWOOD CITY, Calif., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...